Item(by='sterlind', descendants=None, kids=None, score=None, time=1605561526, title=None, item_type='comment', url=None, parent=25115340, text='Some of those options, like monoclonal antibodies, are extremely expensive and hard to produce and distribute at scale, plus they only work early in the course of the disease. I&#x27;m not aware of any small-molecule drugs that have hopes of great efficacy on the horizon. You&#x27;re not going to pump out 150K&#x2F;day doses of MABs.<p>It really is vaccinate or risk dying. The other options are too expensive, too timing-dependent or too ineffective.')